Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
E Jabbour, H Kantarjian - American journal of hematology, 2012 - Wiley Online Library
Abstract Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …
neoplasm with an incidence of one–two cases per 100,000 adults and accounts for∼ 15 …
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
E Jabbour, H Kantarjian - American journal of hematology, 2014 - Wiley Online Library
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …
an incidence of 1–2 cases per 100,000 adults, and accounts for∼ 15% of newly diagnosed …
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2016 - Wiley Online Library
Disease overview: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm with
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …
an incidence of 1‐2 cases per 100,000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Chronic Myeloid Leukemia (CML) is a myeloproliferative
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …
neoplasm with an incidence of 1–2 cases per 100 000 adults. It accounts for approximately …
Chronic myelogenous leukemia
H Kantarjian, E Jabbour, S O'Brien - Molecular Hematology, 2024 - Wiley Online Library
This chapter summarizes our knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …
Long‐term outcomes in the second‐line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
E Jabbour, J Cortes, H Kantarjian - Cancer, 2011 - Wiley Online Library
Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase …
P Jain, H Kantarjian, ML Alattar, E Jabbour… - The Lancet …, 2015 - thelancet.com
Background Several tyrosine kinase inhibitors (TKIs) are available for treatment of patients
with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term …
with chronic myeloid leukaemia in chronic phase (CML-CP). We analysed long-term …
Chronic myeloid leukemia: first‐line drug of choice
E Jabbour - American journal of hematology, 2016 - Wiley Online Library
The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …